Physician profile
Erica Mann
NPI 1255900593
$2,924.79
in general payments reported to CMS, 2019-2025
44 companies · $931 in 2025
The $931 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $131 · 2023: $897 · 2024: $965 · 2025: $931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,518 · Education: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,517.81 |
| Education | $275.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $321.78 | 2024-2025 | |
| Janssen Biotech, INC. | $205.68 | 2023-2025 | Imbruvica, Carvykti, Darzalex |
| Merck Sharp & Dohme LLC | $176.10 | 2023-2025 | Keytruda, Welireg, Reblozyl |
| Incyte Corporation | $155.37 | 2023-2025 | Jakafi, Pemazyre, Monjuvi |
| Aveo Pharmaceuticals, INC. | $142.64 | 2023-2025 | Fotivda |
| Seagen INC. | $136.60 | 2023 | Tukysa |
| Boston Scientific Corporation | $131.00 | 2022 | |
| Daiichi Sankyo INC. | $126.50 | 2023-2025 | Enhertu |
| Glaxosmithkline, LLC. | $125.34 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Abbvie INC. | $122.05 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $110.51 | 2023-2025 | Imfinzi, Wainua |
| Gilead Sciences, INC. | $101.99 | 2023-2024 | Trodelvy |
| Tempus Ai, INC | $95.84 | 2024 | |
| Astellas Pharma US INC | $66.42 | 2024-2025 | Xtandi, Vyloy |
| Bayer Healthcare Pharmaceuticals INC. | $64.74 | 2023-2025 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $63.25 | 2023-2024 | Venclexta, Polivy, Lunsumio |
| Taiho Oncology, INC. | $54.91 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.62 | 2023-2024 | Fruzaqla |
| Genmab U.S., INC. | $48.00 | 2023 | Epkinly |
| Celgene Corporation | $46.94 | 2023-2025 | Pomalyst, Breyanzi |
| Ipsen Biopharmaceuticals, INC | $46.26 | 2024-2025 | Onivyde |
| Eisai INC. | $43.07 | 2023-2025 | |
| Lilly USA, LLC | $35.37 | 2023-2024 | Jaypirca, Verzenio, Retevmo |
| Kite Pharma, INC. | $33.38 | 2024 | Yescarta |
| Puma Biotechnology, INC. | $31.03 | 2023-2024 | |
| Pfizer INC. | $27.22 | 2024 | |
| Tersera Therapeutics LLC | $26.95 | 2023 | Zoladex |
| Sandoz INC. | $24.95 | 2025 | |
| Emd Serono, INC. | $24.46 | 2023 | Tepmetko |
| Alexion Pharmaceuticals, INC. | $24.27 | 2025 | Ultomiris |
| Cumberland Pharmaceuticals, INC. | $23.47 | 2023 | Sancuso |
| Servier Pharmaceuticals LLC | $22.38 | 2023 | |
| Beone Medicines USA, INC. | $21.88 | 2025 | Brukinsa |
| Geron Corporation | $20.85 | 2025 | Rytelo |
| Jazz Pharmaceuticals INC. | $20.37 | 2024 | |
| Stemline Therapeutics INC. | $20.25 | 2023 | Orserdu |
| Immunocore Limited | $19.00 | 2025 | Kimmtrak |
| E.R. Squibb & Sons, L.L.C. | $18.83 | 2024 | Opdivo |
| Adc Therapeutics America, INC. | $18.80 | 2024 | |
| Blueprint Medicines Corporation | $16.52 | 2023 | Ayvakit |
| Array Biopharma INC | $15.67 | 2023 | Mektovi, Braftovi, Xalkori |
| Deciphera Pharmaceuticals INC. | $15.64 | 2023 | Qinlock |
| Secura Bio, INC. | $15.63 | 2023 | Copiktra |
| Sumitomo Pharma America, INC. | $14.26 | 2023 | Orgovyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.